Joel Isaacson & Co’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.08M Buy
86,319
+1,674
+2% +$43.8K 0.06% 137
2026
Q1
$2.38M Sell
84,645
-817
-1% -$21.8K 0.08% 116
2025
Q4
$2.13M Buy
85,462
+5,660
+7% +$143K 0.07% 126
2025
Q3
$2.03M Buy
79,802
+3,089
+4% +$76.2K 0.07% 124
2025
Q2
$1.86M Sell
76,713
-6,285
-8% -$147K 0.08% 116
2025
Q1
$2.1M Sell
82,998
-675
-0.8% -$17.7K 0.1% 97
2024
Q4
$2.22M Buy
83,673
+6,028
+8% +$164K 0.1% 98
2024
Q3
$2.25M Buy
77,645
+1,687
+2% +$49.2K 0.11% 92
2024
Q2
$2.13M Buy
75,958
+141
+0.2% +$3.88K 0.11% 85
2024
Q1
$2.1M Buy
75,817
+4,395
+6% +$122K 0.12% 84
2023
Q4
$2.06M Buy
71,422
+21,336
+43% +$645K 0.13% 80
2023
Q3
$1.66M Buy
50,086
+718
+1% +$25.4K 0.11% 81
2023
Q2
$1.81M Sell
49,368
-3,001
-6% -$117K 0.12% 78
2023
Q1
$2.14M Sell
52,369
-835
-2% -$36.1K 0.15% 67
2022
Q4
$2.73M Buy
53,204
+876
+2% +$42K 0.21% 53
2022
Q3
$2.29M Buy
52,328
+3,351
+7% +$163K 0.2% 54
2022
Q2
$2.57M Sell
48,977
-683
-1% -$34.8K 0.22% 50
2022
Q1
$2.57M Buy
49,660
+793
+2% +$41.1K 0.19% 54
2021
Q4
$2.89M Buy
48,867
+3,384
+7% +$168K 0.2% 54
2021
Q3
$1.96M Buy
45,483
+48
+0.1% +$2.13K 0.15% 68
2021
Q2
$1.78M Buy
45,435
+499
+1% +$19.4K 0.14% 71
2021
Q1
$1.63M Sell
44,936
-709
-2% -$25.2K 0.14% 68
2020
Q4
$1.68M Sell
45,645
-1,128
-2% -$41.4K 0.16% 56
2020
Q3
$1.63M Buy
46,773
+2,658
+6% +$93.2K 0.21% 50
2020
Q2
$1.37M Sell
44,115
-73
-0.2% -$2.48K 0.2% 59
2020
Q1
$1.37M Sell
44,188
-26,050
-37% -$888K 0.24% 49
2019
Q4
$2.61M Sell
70,238
-884
-1% -$31.5K 0.34% 33
2019
Q3
$2.42M Sell
71,122
-6,003
-8% -$218K 0.35% 35
2019
Q2
$3.17M Sell
77,125
-20,358
-21% -$808K 0.46% 28
2019
Q1
$3.93M Buy
97,483
+28,875
+42% +$1.16M 0.57% 27
2018
Q4
$2.79M Buy
68,608
+28,519
+71% +$1.18M 0.44% 29
2018
Q3
$1.68M Sell
40,089
-1,430
-3% -$55K 0.26% 40
2018
Q2
$1.43M Sell
41,519
-180
-0.4% -$6.15K 0.24% 43
2018
Q1
$1.4M Buy
41,699
+2,983
+8% +$103K 0.24% 44
2017
Q4
$1.33M Buy
38,716
+1,374
+4% +$46.9K 0.23% 48
2017
Q3
$1.26M Buy
37,342
+892
+2% +$28.7K 0.23% 49
2017
Q2
$1.16M Sell
36,450
-254
-0.7% -$8.01K 0.22% 51
2017
Q1
$1.19M Buy
36,704
+57
+0.2% +$1.8K 0.23% 50
2016
Q4
$1.13M Sell
36,647
-3,264
-8% -$99.6K 0.23% 49
2016
Q3
$1.28M Sell
39,911
-1,105
-3% -$36.9K 0.26% 38
2016
Q2
$1.37M Buy
41,016
+350
+0.9% +$11.2K 0.29% 36
2016
Q1
$1.14M Sell
40,666
-804
-2% -$23K 0.25% 43
2015
Q4
$1.27M Sell
41,470
-3,036
-7% -$95.5K 0.31% 41
2015
Q3
$1.33M Buy
44,506
+874
+2% +$28K 0.35% 37
2015
Q2
$1.39M Buy
43,632
+3,099
+8% +$101K 0.36% 36
2015
Q1
$1.34M Buy
40,533
+672
+2% +$21.4K 0.34% 40
2014
Q4
$1.18M Buy
39,861
+8,181
+26% +$235K 0.32% 40
2014
Q3
$889K Buy
31,680
+918
+3% +$25.8K 0.27% 47
2014
Q2
$866K Sell
30,762
-439
-1% -$12.5K 0.27% 47
2014
Q1
$951K Buy
31,201
+1,883
+6% +$56.1K 0.32% 42
2013
Q4
$852K Buy
29,318
+1,295
+5% +$37.7K 0.31% 40
2013
Q3
$764K Buy
28,023
+8,797
+46% +$239K 0.31% 42
2013
Q2
$511K Buy
+19,226
New +$531K 0.24% 49

Other funds holding PFE

Joel Isaacson & Co's PFE Position: Q2 2026 in Review

Joel Isaacson & Co increased its Pfizer (PFE) stake by 2% in Q2 2026, buying an estimated $43.8K and bringing the position to 86,319 shares worth $2.08M. The position accounts for 0.06% of the portfolio, ranked #137.

Joel Isaacson & Co first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.93M in Q1 2019. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Joel Isaacson & Co held 86,319 shares of Pfizer worth $2.08M as of Q2 2026.
  • Joel Isaacson & Co bought 1,674 Pfizer shares in Q2 2026, an estimated $43.8K.
  • Pfizer made up 0.06% of Joel Isaacson & Co's portfolio in Q2 2026, its #137 holding.
  • Joel Isaacson & Co first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Joel Isaacson & Co's Pfizer position peaked at $3.93M in Q1 2019.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Joel Isaacson & Co's 13F filing for Q2 2026, filed 4 Aug 2026.